SPA
TBPH icon

Sherbrooke Park Advisers’s Theravance Biopharma TBPH Stock Holding History

Sherbrooke Park Advisers’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,189
Closed -$178K – 511
2025
Q3 		$178K Buy
+12,189
New +$154K 0.08% 400
2024
Q4 		– Sell
-34,746
Closed -$280K – 1150
2024
Q3 		$280K Sell
34,746
-17,772
-34% -$154K 0.06% 597
2024
Q2 		$445K Buy
+52,518
New +$474K 0.08% 467

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Sherbrooke Park Advisers's TBPH Position: Q4 2025 in Review

Sherbrooke Park Advisers sold out of Theravance Biopharma (TBPH) in Q4 2025, closing a stake of 12,189 shares — an estimated $178K sold.

Sherbrooke Park Advisers first reported a position in TBPH in Q2 2024 and held it in 3 quarters. The position peaked at $445K in Q2 2024. 169 funds tracked by Wall St. Rank hold TBPH as of Q4 2025.

  • Sherbrooke Park Advisers reported no remaining Theravance Biopharma position as of Q4 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 12,189 Theravance Biopharma shares in Q4 2025, an estimated $178K.
  • Sherbrooke Park Advisers first reported a position in Theravance Biopharma in Q2 2024 and held it in 3 quarters.
  • Sherbrooke Park Advisers's Theravance Biopharma position peaked at $445K in Q2 2024.
  • 169 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.